Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ibufenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 5/20 | 0.58 |
| ▸ | PTGS2 known ✓ | P35354 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.58 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.58 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ALB | P02768 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | RARB | P10826 | 1/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.58 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibufenac SCHEMBL24244 | 0.98 | PTGS1 (0.60) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| Ibufenac SCHEMBL11571262 | 0.96 | PTGS1 (0.58) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| Ibufenac SCHEMBL2528574 | 0.96 | PTGS1 (0.58) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL25146345 | 0.92 | PTGS1 (0.62) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| Ibuprofen SCHEMBL8210899 | 0.86 | PTGS1 (0.83) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL28872737 | 0.83 | ANPEP (0.55) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| Ibuprofen SCHEMBL28254474 | 0.83 | PTGS1 (0.78) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| Hydrogen Peroxide SCHEMBL9581174 | 0.82 | PTGS1 (0.64) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL9577298 | 0.82 | PTGS1 (0.56) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| Methane SCHEMBL2338589 | 0.82 | EPHX1 (0.59) | PTGS1PTGS2LMNACYP2C9AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260090584-A1 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4590371-A2 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | Scientific Horizons consulting LLC (US) | 2025-07-30 | — | — | EP | claimed |
| WO-2024064885-A2 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2024-03-28 | — | — | WO | claimed |
| CN-114438540-A | Application of photoelectrode loaded with Ag nano particles in photoelectrochemical synthesis of aromatic carboxylic acid | 中国科学院理化技术研究所 | 2022-05-06 | — | — | CN | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| EP-1503714-A4 | LOW PROFILE COMBINATION DEVICE FOR GASTROSTOMY OR JEJUNOSTOMY APPLICATIONS HAVING ANTI-GRANULOMA FORMATION CHARACTERISTICS | PHILADELPHIA CHILDREN HOSPITAL (US) | 2007-01-24 | — | — | EP | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060078575-A1 | Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics | GOLDBERG ELIZABETH A | 2006-04-13 | — | — | US | claimed |
| US-20060045822-A1 | Plasma polymerization for encapsulating particles | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-03-02 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| EP-1503714-A2 | LOW PROFILE COMBINATION DEVICE FOR GASTROSTOMY OR JEJUNOSTOMY APPLICATIONS HAVING ANTI-GRANULOMA FORMATION CHARACTERISTICS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2005-02-09 | — | — | EP | claimed |
| US-20040024363-A1 | Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2004-02-05 | — | — | US | claimed |
| WO-2003088920-A2 | LOW PROFILE COMBINATION DEVICE FOR GASTROSTOMY OR JEJUNOSTOMY APPLICATIONS HAVING ANTI-GRANULOMA FORMATION CHARACTERISTICS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2003-10-30 | — | — | WO | claimed |
| US-20030099682-A1 | Apparatus and method for control of tissue/implant interactions | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-05-29 | — | — | US | claimed |
| US-6497729-B1 | SELF-ASSEMBLED BIOACTIVE POLYMER; PROSTHETICS; DRUG DELIVERY | THE UNIVERSITY OF CONNECTICUT | 2002-12-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | PTGS1 4504/4885PTGS2 3949/4885LMNA 1769/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | PTGS1 3413/4885PTGS2 3503/4885LMNA 2024/4885 |
| US-20260090584-A1 | SYSTEMS AND METHODS FOR ESTIMATING AEROSOLIZATION EMISSION | TMCO1, TANK, SARAF | PTGS1 4282/4885PTGS2 2230/4885LMNA 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.